Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $47,983 | $3,407 | $3,563 | $5,494 |
| % Growth | 1,308.4% | -4.4% | -35.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $47,983 | $3,407 | $3,563 | $5,494 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $7,189 | $6,453 | $7,517 | $5,685 |
| G&A Expenses | $2,818 | $4,561 | $3,365 | $3,991 |
| SG&A Expenses | $2,860 | $4,637 | $3,419 | $4,115 |
| Sales & Mktg Exp. | $60 | $58 | $27 | $53 |
| Other Operating Expenses | $4,078 | $0 | -$50 | $0 |
| Operating Expenses | $14,127 | $11,090 | $10,886 | $10,445 |
| Operating Income | $33,856 | -$7,683 | -$7,323 | -$4,306 |
| % Margin | 70.6% | -225.5% | -205.5% | -78.4% |
| Other Income/Exp. Net | -$2,918 | -$1,861 | -$1,938 | -$2,633 |
| Pre-Tax Income | $30,938 | -$9,544 | -$9,261 | -$6,939 |
| Tax Expense | $5,538 | $13 | $13 | $11 |
| Net Income | $25,400 | -$9,557 | -$9,274 | -$6,950 |
| % Margin | 52.9% | -280.5% | -260.3% | -126.5% |
| EPS | 1.36 | -0.51 | -0.52 | -0.39 |
| % Growth | 366.7% | 1.9% | -33.3% | – |
| EPS Diluted | 1.36 | -0.51 | -0.52 | -0.39 |
| Weighted Avg Shares Out | 18,563 | 18,563 | 17,845 | 17,845 |
| Weighted Avg Shares Out Dil | 18,563 | 18,563 | 17,845 | 17,845 |
| Supplemental Information | – | – | – | – |
| Interest Income | $138 | $0 | $2,001 | $1,988 |
| Interest Expense | $4,353 | $0 | $0 | $0 |
| Depreciation & Amortization | $96 | $96 | $35 | $102 |
| EBITDA | $33,526 | -$7,587 | -$7,288 | -$4,204 |
| % Margin | 69.9% | -222.7% | -204.5% | -76.5% |